C4 Therapeutics, Inc. (CCCC)
Automate Your Wheel Strategy on CCCC
With Tiblio's Option Bot, you can configure your own wheel strategy including CCCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CCCC
- Rev/Share 0.5616
- Book/Share 2.7549
- PB 0.5517
- Debt/Equity 0.3298
- CurrentRatio 5.6966
- ROIC -0.3937
- MktCap 107930792.0
- FreeCF/Share -1.1365
- PFCF -1.3407
- PE -1.0425
- Debt/Assets 0.2014
- DivYield 0
- ROE -0.4586
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CCCC | Wells Fargo | Equal Weight | Overweight | $8 | $12 | Dec. 19, 2024 |
News
C4 Therapeutics: An Entry Point If There's Ever Going To Be One
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Positive
CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.
Read More
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.
Read More
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level
Read More
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026
Read More
C4 Therapeutics to Participate in Upcoming March Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.
Read More
About C4 Therapeutics, Inc. (CCCC)
- IPO Date 2020-10-02
- Website https://www.c4therapeutics.com
- Industry Biotechnology
- CEO Andrew J. Hirsch
- Employees 110